Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM

NCT ID: NCT05417841

Last Updated: 2025-12-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 218 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-23
• Study Completion Date: 2025-08-15

Brief Summary

In this multicenter, randomized, open-label, parallel-controlled, non-inferiority clinical trial, the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with degludec/insulin aspart (IDegAsp) once daily plus insulin aspart (IAsp) twice daily after 16weeks of treatment in patients with type 2 diabetes mellitus. This trial will enable primary assessment of the clinically relevant endpoint of a change in HbA1c.

Detailed Description

The objective of the current study is to investigate the efficacy and safety of IDegAsp twice daily compared with IDegAsp once daily plus IAsp twice daily for 16 weeks in patients with type 2 diabetes mellitus. The primary endpoint in this study is the change from baseline in HbA1c. Patients with type 2 diabetes who meet the entry criteria are planned for inclusion in this trial. Approximately 224 patients will be enrolled in the study. Patients who qualify will be randomized to IDegAsp group or IDegAsp + IAsp group. Duration of treatment includes 3-week screening period, 16-week treatment observation period and 1-week follow-up.

Conditions

Type 2 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IDegAsp group

IDegAsp twice daily

Group Type: EXPERIMENTAL

Insulin Degludec and Insulin Aspart Injection

Intervention Type: DRUG

To evaluate the efficacy and safety of the IDegAsp BID in T2DM

IDegAsp + IAsp group

IDegAsp once daily plus IAsp twice daily

Group Type: ACTIVE_COMPARATOR

Insulin Degludec and Insulin Aspart Injection

Intervention Type: DRUG

To evaluate the efficacy and safety of the IDegAsp BID in T2DM

Insulin Aspart Injection

Intervention Type: DRUG

To evaluate the efficacy and safety of the IDegAsp QD plus IAsp BID in T2DM

Interventions

Insulin Degludec and Insulin Aspart Injection

To evaluate the efficacy and safety of the IDegAsp BID in T2DM

Intervention Type: DRUG

Insulin Aspart Injection

To evaluate the efficacy and safety of the IDegAsp QD plus IAsp BID in T2DM

Intervention Type: DRUG

Other Intervention Names

Ryzodeg®; NovoRapid®

Eligibility Criteria

Inclusion Criteria

• 1. Informed consent has been obtained before any trial-related activities;
• 2. Patients aged 18~75 years old (including 18 years old and 75 years old);
• 3. Clinical diagnosis of type 2 diabetes ≥ 6 months according to WHO diagnostic criteria before screening;
• 4. Use basal insulin once a day with or without other hypoglycemic drugs for at least 3 months before randomization;
• 5. Glycated hemoglobin between 7.0%~10.0% within 3 month before randomization (including the critical value);
• 6. Body mass index (BMI)≤40.0kg/m2;

Exclusion Criteria

• 1. Suffering from type 1 diabetes, or special type of diabetes;
• 2. Known premixed insulin or IDegAsp used 3 month before randomization;
• 3. Changes in concomitant medications that are expected to significantly interfere with glucose metabolism;
• 4. Known or suspected subjects are allergic to test drugs, excipients or related similar products and excipients;
• 5. Cardiovascular and cerebrovascular disease, defined as: congestive heart failure (NYHA class III-IV), diagnosis of unstable angina pectoris, stroke and/or myocardial infarction within 6 months before screening; or planned/coronary artery , carotid artery, peripheral artery revascularization;
• 6. According to the judgment of the investigator, repeated hypoglycemia perception impairment and severe hypoglycemia events occurred before screening;
• 7. Abnormal and clinically significant hemoglobin laboratory test results;
• 8. Hepatic insufficiency, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 times the upper limit of the normal range at screening; renal insufficiency, defined as (but not limited to) serum creatinine Levels ≥1.5mg/dL (132umol/L, men) and ≥1.4mg/dL (123umol/L, women), or massive proteinuria (>2 g/day);
• 9. Uncontrolled/untreated hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg) before randomization;
• 10. Two or more events of ketoacidosis or hyperglycemia and hyperosmolar state requiring hospitalization within 6 months prior to screening, or significant diabetic complications, such as symptomatic autonomic neuropathy, diabetic gastric mildew paralysis, proliferative retinopathy, etc. occured;
• 11. According to the judgment of the investigator, significant changes in lifestyle are expected during the trial period, such as shift work (including persistent night/evening shift work) and highly irregular diet and living habits;
• 12. Pregnant or breastfeeding women; those who have a pregnancy plan during the entire trial period and are unwilling to take one or more non-drug contraceptive measures (such as complete abstinence, contraceptive ring, partner ligation, etc.) during the trial;
• 13. Participate in any clinical trial within the past 3 months;
• 14. Those who are not suitable to participate in the trial according to the investigator's judgment, or any clinically significant disease or condition that the investigator believes may affect the results of the trial, such as: a history of hemolytic anemia or sickle cell anemia, a previous history of tumor or cancer Patients with a medical history, patients with a known history of alcohol, drug or drug abuse, blood transfusions or severe blood loss within the first 3 months of screening, or patients with poor adherence in the judgment of the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hebei General Hospital

Shijiazhuang, Hebei, China

Jilin University Sino-Japanese Friendship Hospital

Changchun, Jilin, China

The Second Affiliated Medical College of Xi'an Jiaotong University

Xi'an, Shaanxi, China

Aerospace general hospital

Beijing, , China

Beijing Boai Hospital

Beijing, , China

Beijing Hospital

Beijing, , China

Peking university shougang hospital

Beijing, , China

Countries

China

Other Identifiers

MLD-C-21003

Identifier Type: -

Identifier Source: org_study_id